Literature DB >> 30718938

Generation of High Concentrations of Respirable Solid-Phase Aerosols from Viscous Fluids.

Xin Heng1, Donovan B Yeates1.   

Abstract

High outputs of respirable solid-phase aerosols were generated from viscous solutions or suspensions of low and high molecular weight polyvinylprrolidone (PVP) solutions, 10% (w/v) albumin and, gamma-globulin solutions as well as 10.3% (w/v) surfactant suspensions. A central fluid flow was aerosolized by coaxial converging compressed air. The water was evaporated from the droplets using warm dilution air and infrared radiation. The resulting aerosol particles were concentrated using a virtual impactor. The aerosols were generated at fluid flow rates between 1 and 3 ml/min and delivered at a flow rate of 44 l/min as 2.6 - 3.6 μm MMAD aerosols with geometric standard deviations between 1.5 and 2. Increases in viscosity over the range of 4 to 39 cSt caused a modest increase in MMAD. Increases in aerosol exit orifice diameter was associated with a decrease in aerosol diameter. Increases in compressed air pressure caused a decrease in aerosol diameter. Increases in fluid flow rate resulted modest increases in MMAD together with proportional increases in output mass. Aerosolizing 10% 8 kDa PVP at 3 ml/min resulted in the delivery of 193 mg/min of PVP at 64% efficiency enabling 1.2 g to be collected in 7 min. Aerosolizing 10.3% surfactant suspensions at 3 ml/min resulted in the delivery of up to 163 mg/min with 59% efficiency. The surface tension of the surfactant was not changed by these processes. SEM showed dimpled particles of PVP, albumin and gamma globulin indicating that their aerodynamic diameter was less than their morphometric diameter.

Entities:  

Keywords:  ARDS; aerosol drug delivery; antibodies; macromolecules; proteins; spray drying; surfactant

Year:  2018        PMID: 30718938      PMCID: PMC6358172          DOI: 10.1080/02786826.2018.1488078

Source DB:  PubMed          Journal:  Aerosol Sci Technol        ISSN: 0278-6826            Impact factor:   2.908


  41 in total

1.  Rationale for the selection of an aerosol delivery system for gene delivery.

Authors:  Yvonne K Lentz; Thomas J Anchordoquy; Corinne S Lengsfeld
Journal:  J Aerosol Med       Date:  2006

Review 2.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

3.  The influence of fluid physicochemical properties on vibrating-mesh nebulization.

Authors:  Thu Ghazanfari; Abdelbary M A Elhissi; Zhiyi Ding; Kevin M G Taylor
Journal:  Int J Pharm       Date:  2007-03-06       Impact factor: 5.875

4.  Revision of capillary cone-jet physics: electrospray and flow focusing.

Authors:  Alfonso M Gañán-Calvo; José M Montanero
Journal:  Phys Rev E Stat Nonlin Soft Matter Phys       Date:  2009-06-15

5.  Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis.

Authors:  Birgitte Frederiksen; Tacjana Pressler; Annelise Hansen; Christian Koch; Niels Høiby
Journal:  Acta Paediatr       Date:  2006-09       Impact factor: 2.299

6.  A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis.

Authors:  Hiromi Tomioka; Youichirou Kuwata; Kazufumi Imanaka; Kimio Hashimoto; Hisashi Ohnishi; Kimihide Tada; Hiroko Sakamoto; Hironobu Iwasaki
Journal:  Respirology       Date:  2005-09       Impact factor: 6.424

7.  Effect of energy on propylene glycol aerosols using the capillary aerosol generator.

Authors:  X Shen; M Hindle; P R Byron
Journal:  Int J Pharm       Date:  2004-05-04       Impact factor: 5.875

8.  The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the delivery of pumactant for inhalation therapy.

Authors:  Paul M Young; Jim Thompson; Derek Woodcock; Mo Aydin; Robert Price
Journal:  J Aerosol Med       Date:  2004

9.  Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.

Authors:  Bart J Rijnders; Jan J Cornelissen; Lennert Slobbe; Martin J Becker; Jeanette K Doorduijn; Wim C J Hop; Elisabeth J Ruijgrok; Bob Löwenberg; Arnold Vulto; Pieternella J Lugtenburg; Siem de Marie
Journal:  Clin Infect Dis       Date:  2008-05-01       Impact factor: 9.079

10.  Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency.

Authors:  P Brand; M Schulte; M Wencker; C H Herpich; G Klein; K Hanna; T Meyer
Journal:  Eur Respir J       Date:  2009-02-27       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.